April 01, 2025

FDA Monthly Round-Up: Key March Updates

March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.

Conexiant

March 31, 2025

Tariff Threat: Drugs Could Cost U.S. $750M More

New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.

Conexiant

March 25, 2025

Not All Plant-Based Diets Are Equal

Higher adherence to a healthy plant-based diet linked to lower IBD risk.

Conexiant

March 25, 2025

Not All Plant-Based Diets Are Equal

Higher adherence to a healthy plant-based diet linked to lower IBD risk.

Conexiant

March 21, 2025

FDA Approves Guselkumab for Crohn’s Disease

The FDA has approved guselkumab (TREMFYA®) for moderately to severely active Crohn’s disease, supported by Phase 3 trial data showing clinical and endoscopic superiority over ustekinumab.

Conexiant

March 19, 2025

Depression Linked to Faster Physical Health Condition Accrual

People with a history of depression accumulate chronic physical conditions at a 30% faster rate than those without, according to data.

Conexiant

March 19, 2025

Study: Sex Differences in Physician Suicide

Researchers found that female physicians had a significantly higher suicide risk than female nonphysicians.

Conexiant

March 17, 2025

Life’s Simple 7 Adherence: Constipation & Diarrhea Analysis

"As we move toward a more holistic approach to health care, integrating lifestyle modifications into clinical practice could lead to improved gastrointestinal health outcomes."

Conexiant

March 13, 2025

FDA Chief Counsel Resigns Two Days In

U.S. FDA's chief counsel resigns amidst controversy surrounding her appointment and connections to mifepristone during the Biden administration.

Reuters